新型靶向降脂药物:Evolocumab临床进展

Novel Targeted Lipid-lowering Drug: Clinical Progress of Evolocumab

冠心病仍然为威胁人类健康的疾病之一,其中血清低密度脂蛋白胆固醇(LDL-C)升高是导致冠心病的主要危险因素,目前降脂治疗的药物主要为他汀类和依折麦布,但仍有很多患者存在高LDL-C,且有一部分患者不能耐受药物不良反应导致停药。新型靶向降脂药物evolocumab(前蛋白转化酶枯草溶菌素9抑制剂)作为降脂的新药之一,能特异性地与LDL-C受体结合,相关3期临床试验证实了该药能显著降低LDL-C,已得到欧盟及美国食品药品监督管理局的批准,同时在远期初步显示了能降低心血管事件,为治疗冠心病带来了新的希望。现就evolocumab的试验进展做一简述,为临床用药提供指导。

Coronary heart disease is still one of the diseases that threatens human heahh, and the elevated serum low-density lipoprorein cholesterol（LDL-C） is the leading cause of coronary heart disease. The current lipid-lowering drugs are statins and ezetimibe, but there are still many patients with high LDL-C, and some patients are unable to tolerate drug＇ s side effects that lead to withdrawal. The new targeted lipid-lowering drug evolocumab （PCSK9 inhibitor） has a new drug lipid-lowering, specificity and LDL-C receptor binding. Phase 3 clinical trials confirmed that the drug can significantly reduce LDL-C, and has received EU and FDA approval. Meanwhile the initial results show that the cardiovascular events can be reduced in a long-term period, and brings the new hope for the treatment of coronary heart disease. The progress of evolocumab will be briefly discussed in this paper to provide guidance for the clinical use.